NIH R01 · 2024
There is substantial need to improve treatment for opioid use disorder (OUD). Buspirone is a mechanistically supported medication with robust preclinical and preliminary clinical support for treating opioid withdrawal and decreasing relapse. Buspirone has the utility to treat both acute and protracted withdrawal periods. We are experts in the measurement, evaluation and treatment of opioid withdrawal symptoms and have recently completed an RCT pilot study (n=16) which provides the initial safety, feasibility, and efficacy data to support a more thorough evaluation of buspirone to mitigate withdrawal when administered as an adjunct to a residential stepwise opioid taper. We propose a…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.